Epidermal growth factor receptor and B7-H3 expression in esophageal squamous tissues correlate to patient prognosis

• Published in: OncoTargets and therapy Vol. 9; pp. 6257 - 6263
• Main Authors: Song, Jianxiang, Shi, Woda, Zhang, Yajun, Sun, Mingzhong, Liang, Xiaodong, Zheng, Shiying
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2016; Taylor & Francis Ltd; Dove Medical Press
• Subjects: Antigens; Care and treatment; Cell adhesion & migration; Chemotherapy; Development and progression; Epidermal growth factor; Esophageal cancer; Gene expression; Genetic aspects; Health aspects; Heart surgery; Immune system; Kinases; Lymphatic system; Medical prognosis; Metastasis; Mortality; Original Research; Pathology; Patients; Prognosis; Radiation therapy; Squamous cell carcinoma; Tumors; China; costimulatory molecule B7-H3; esophageal squamous cell carcinoma; immunohistochemistry; prognosis; epidermal growth factor receptor
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/ott.s111691

Biomarkers that can serve as diagnostic and prognostic indicators of esophageal squamous cell carcinoma (ESCC) are urgently needed to help improve patient outcomes. Here, the expression of epidermal growth factor receptor (EGFR) and costimulatory molecule B7-H3, both of which have been implicated in tumor onset and progression in certain tumors, was investigated in relation to the clinical characteristics and survival outcomes of patients with ESCC. ESCC tissue samples were analyzed for 100 patients. Tumor and patient characteristics were recorded. Tissues were investigated for EGFR and B7-H3 staining by immunohistochemistry. Patients were followed for up to 96 months to determine overall survival (OS) and progression-free survival (PFS). High expression for EGFR (68.0%) and B7-H3 (66.0%) was observed in the majority of cases. High expression of either EGFR or B7-H3 was correlated with tumor invasion depth and clinical stage ( <0.05). Further, high expression of either EGFR or B7-H3 was correlated with worse survival outcomes. The estimated OS (38.1 months) and PFS (13.4 months) of patients with high expression of EGFR were lower than those of patients with low expression (69.3 and 68.1 months, <0.05). The estimated OS (31.1 months) and PFS (13.1 months) of patients with high expression of B7-H3 were also lower than those of patients with low expression (69.3 and 66.6 months, <0.05). Indeed, Cox multiple regression showed that OS and PFS were correlated with EGFR (relative risk =1.853, 1.875, respectively) and B7-H3 (relative risk =1.886, 2.061, respectively) (all <0.05) expression level. Thus, EGFR and B7-H3 are highly expressed in tumor tissues of patients with ESCC. Their expression levels are correlated with tumor severity and survival, and therefore these may be viable biomarkers to aid in prognosis determination.